ClinicalTrials.gg
CompletedNCT02808819MELTEMIUpdated Apr 13, 2021Results posted

A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist

A Phase 3 interventional study of Benralizumab and Benralizumab in Asthma, sponsored by AstraZeneca. Completed at 178 sites in 15 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-04-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
447
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
8th of 39
447 · median 128
Started
2016
with 4 others
Phase 3
20 of 39
1 open now
Registered
14th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 8th largest by enrollment, is one of 5 that started in 2016, is one of 20 in phase 3, and was the 14th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor study D3250C00021 (BORA, NCT02258542).

Read the detailed description

This is an open-label safety extension study designed to evaluate the safety and tolerability of a fixed 30 mg dose of benralizumab administered subcutaneously (SC) in severe asthma patients on inhaled corticosteroid and long-acting β2 agonist (ICS-LABA) therapy with or without chronic oral corticosteroids (OCS) and/or other asthma controllers. All patients will receive active drug on the same dosing regimen they received in BORA (NCT02258542). In order to protect the blind of BORA, patients will remain blinded to treatment regimen allocation until they have completed all end of treatment (EOT) assessments in BORA and signed informed consent for participation in this study, after which treatment allocation will be unblinded to both the investigator and the patient.

03

Conditions studied

  • Asthma

Keywords

  • Asthma
  • Bronchial Diseases
  • Respiratory Tract Diseases
  • Lung Diseases
  • Obstructive Lung Diseases
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • for study participation must be obtained prior to any study related procedures being performed and according to international guidelines and/or applicable European Union guidelines.
  • Female and male patients who have completed at least 16 and not more than 40 weeks in Study D3250C00021.
  • Women of (WOCBP) must agree to use an effective form of throughout the study duration and for 16 weeks after the last dose of Product (IP)
  • For WOCBP only: Have a negative urine pregnancy test prior to administration of IP at Visit 1.
  • All male patients who are sexually active must agree to use a double barrier method of contraception (condom with spermicide) from the first dose of IP until 16 weeks after their last dose.

Exclusion criteria

Exclusion Criteria:

  • Any disorder including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric or major physical impairment that is not stable in the opinion of the Investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the study or their interpretations
    • Impede the patient's ability to complete the entire duration of study
  • A helminth parasitic infection diagnosed during a predecessor study that has either required hospitalization, has not been treated, has been incompletely treated or has failed to respond to standard of care therapy
  • Any change in physical examination, vital signs, , hematology, clinical chemistry, or urinalysis during the predecessor study which in the opinion of the investigator may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or interfere with the patient's ability to complete the entire duration of the study
  • Current or malignancy that developed during the predecessor study (subjects that had basal cell carcinoma, localized squamous cell carcinoma of the skin which was resected for cure, or in situ carcinoma of the cervix that has been treated/cured will not be excluded).
  • Receipt of within 30 days prior to initiation of treatment in this study, during the treatment period, and for 16 weeks (5 half-lives) after the last dose of the IP
  • Receipt of immunoglobulin or blood products within 30 days prior to Visit 1
  • Planned major surgical procedures during the conduct of the study
  • Previous participation in the present study
  • Concurrent enrolment in another drug-related interventional clinical trial
  • AstraZeneca staff involved in the planning and/or conduct of the study
  • Employees of the study center or any other individuals involved with the conduct of the study or immediate family members of such individuals
  • Patients with important protocol deviations in the predecessor study at the discretion of the Sponsor
  • Patients with ongoing serious adverse events (SAEs) from the prior study should not be enrolled into the this extension study until the SAE has resolved
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
447 participants (actual)

Study arms

  • Other
    Benralizumab Arm A

    Benralizumab administered subcutaneously every 4 weeks

    Biological: Benralizumab

  • Other
    Benralizumab Arm B

    Benralizumab administered subcutaneously every 8 weeks

    Biological: Benralizumab

Interventions

  • BiologicalBenralizumab

    Benralizumab administered subcutaneously every 4 weeks

  • BiologicalBenralizumab

    Benralizumab administered subcutaneously every 8 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Basophils, Full Analysis Set

    Change from baseline in hematologic lab parameter of Basophils.

    Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.

  2. Change From Baseline in Leukocytes, Full Analysis Set

    Change from baseline in hematologic lab parameter of Leukocytes.

    Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.

  3. Change From Baseline in Lymphocytes, Full Analysis Set

    Change from baseline in hematologic lab parameter of Lymphocytes.

    Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.

  4. Change From Baseline in Neutrophils, Full Analysis Set

    Change from baseline in hematologic lab parameter of Neutrophils.

    Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.

  5. Change From Baseline in Monocytes, Full Analysis Set

    Change from baseline in hematologic lab parameter of Monocytes.

    Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.

  6. Change From Baseline in Platelets, Full Analysis Set

    Change from baseline in hematologic lab parameter of Platelets.

    Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.

  7. Change From Baseline in Hematocrit, Full Analysis Set

    Change from baseline in hematologic lab parameter of Hematocrit.

    Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.

  8. Change From Baseline in Erythrocytes, Full Analysis Set

    Change from baseline in hematologic lab parameter of Erythrocytes.

    Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.

  9. Change From Baseline in Hemoglobin, Full Analysis Set

    Change from baseline in hematologic lab parameter of Hemoglobin.

    Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.

  10. Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set

    Change from baseline in chemistry test ALT.

    Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.

  11. Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set

    Change from baseline in chemistry test AST.

    Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.

  12. Change From Baseline in Bilirubin, Full Analysis Set

    Change from baseline in chemistry test Bilirubin.

    Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.

Secondary outcomes

  1. Number of Participants With Asthma Exacerbations During Study Period

    Asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit

    Time frame: From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with asthma exacerbation during this period is presented.

  2. Number of Participants Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period

    Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma

    Time frame: From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with health care encounters during this period is presented.

  3. Change of Blood Eosinophils Count

    Change from Baseline to End of Treatment in blood eosinophils count.

    Time frame: From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.

  4. Number of Participants With Anti-drug Antibodies (ADA) Responses During the Study

    Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study

    Time frame: From week 0 to week 184 in study treatment period and plus 12 weeks follow up period

  5. Duration of Exposure

    Duration of exposure

    Time frame: From week 0 to week 184 in study treatment period

07

Results

Posted Apr 13, 2021
Limitations and caveats
All participants in this study had to complete treatment in predecessor studies. Therefore selection bias may exist. Baseline is defined for this study's entry value, not the value prior to Benralizumab treatment. All participants have been treated with Benralizumab prior to this study's entry.

Participant flow

447 patients enrolled in MELTEMI, 1 patient from Czech Republic was not treated, thus 446 patients received at least 1 dose of IP. Among these treated participants, 347 were from studies SIROCCO(NCT01928771)/CALIMA(NCT01914757) and 99 were from study ZONDA(NCT02075255).

Participant flow — Overall Study
MilestoneBenra 30 mg q.4 WeeksBenra 30 mg q.8 Weeks
Started220226
Treated220226
Completed189195
Not completed3131
Withdrew: Eg. no treatment efficacy on asthma54
Withdrew: Withdrawal by subject1013
Withdrew: Site terminated by sponsor20
Withdrew: Pregnancy10
Withdrew: Lost to follow-up16
Withdrew: Protocol violation01
Withdrew: Development of study-specific withdrawal criteria83
Withdrew: Death10
Withdrew: Adverse event34

Outcome measures

PrimaryChange From Baseline in Basophils, Full Analysis Set

Change from baseline in hematologic lab parameter of Basophils.

Time frame:
From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Basophils, Full Analysis Set
10^9 cells/LBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Change From Baseline in Basophils, Full Analysis Set0.014 ± 0.02290.012 ± 0.02430.013 ± 0.0236
PrimaryChange From Baseline in Leukocytes, Full Analysis Set

Change from baseline in hematologic lab parameter of Leukocytes.

Time frame:
From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Leukocytes, Full Analysis Set
10^9 cells/LBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Change From Baseline in Leukocytes, Full Analysis Set-0.254 ± 2.0446-0.498 ± 1.7217-0.377 ± 1.8896
PrimaryChange From Baseline in Lymphocytes, Full Analysis Set

Change from baseline in hematologic lab parameter of Lymphocytes.

Time frame:
From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Lymphocytes, Full Analysis Set
10^9 cells/LBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Change From Baseline in Lymphocytes, Full Analysis Set-0.098 ± 0.5479-0.142 ± 0.6544-0.121 ± 0.6038
PrimaryChange From Baseline in Neutrophils, Full Analysis Set

Change from baseline in hematologic lab parameter of Neutrophils.

Time frame:
From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Neutrophils, Full Analysis Set
10^9 cells/LBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Change From Baseline in Neutrophils, Full Analysis Set-0.237 ± 1.8765-0.392 ± 1.4802-0.315 ± 1.6866
PrimaryChange From Baseline in Monocytes, Full Analysis Set

Change from baseline in hematologic lab parameter of Monocytes.

Time frame:
From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Monocytes, Full Analysis Set
10^9 cells/LBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Change From Baseline in Monocytes, Full Analysis Set0.055 ± 0.18350.056 ± 0.17660.055 ± 0.1798
PrimaryChange From Baseline in Platelets, Full Analysis Set

Change from baseline in hematologic lab parameter of Platelets.

Time frame:
From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Platelets, Full Analysis Set
10^9 cells/LBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Change From Baseline in Platelets, Full Analysis Set9.1 ± 41.7211.9 ± 36.1310.5 ± 38.98
PrimaryChange From Baseline in Hematocrit, Full Analysis Set

Change from baseline in hematologic lab parameter of Hematocrit.

Time frame:
From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Reported as:
Mean · [ratio]
Change From Baseline in Hematocrit, Full Analysis Set
[ratio]Benra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Change From Baseline in Hematocrit, Full Analysis Set-0.002 ± 0.0269-0.003 ± 0.0260-0.003 ± 0.0264
PrimaryChange From Baseline in Erythrocytes, Full Analysis Set

Change from baseline in hematologic lab parameter of Erythrocytes.

Time frame:
From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Reported as:
Mean · 10^12 cells/L
Change From Baseline in Erythrocytes, Full Analysis Set
10^12 cells/LBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Change From Baseline in Erythrocytes, Full Analysis Set-0.008 ± 0.2922-0.054 ± 0.2614-0.031 ± 0.2776
PrimaryChange From Baseline in Hemoglobin, Full Analysis Set

Change from baseline in hematologic lab parameter of Hemoglobin.

Time frame:
From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Reported as:
Mean · g/L
Change From Baseline in Hemoglobin, Full Analysis Set
g/LBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Change From Baseline in Hemoglobin, Full Analysis Set2.6 ± 8.921.2 ± 8.371.9 ± 8.66
PrimaryChange From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set

Change from baseline in chemistry test ALT.

Time frame:
From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Reported as:
Mean · ukat/L
Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set
ukat/LBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set0.007 ± 0.20600.004 ± 0.21180.005 ± 0.2086
PrimaryChange From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set

Change from baseline in chemistry test AST.

Time frame:
From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Reported as:
Mean · ukat/L
Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set
ukat/LBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set-0.021 ± 0.1258-0.018 ± 0.1280-0.020 ± 0.1267
PrimaryChange From Baseline in Bilirubin, Full Analysis Set

Change from baseline in chemistry test Bilirubin.

Time frame:
From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Reported as:
Mean · umol/L
Change From Baseline in Bilirubin, Full Analysis Set
umol/LBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Change From Baseline in Bilirubin, Full Analysis Set-0.451 ± 3.0980-0.297 ± 3.3972-0.374 ± 3.2486
SecondaryNumber of Participants With Asthma Exacerbations During Study Period

Asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit

Time frame:
From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with asthma exacerbation during this period is presented.
Reported as:
Count of participants · Participants
Number of Participants With Asthma Exacerbations During Study Period
ParticipantsBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Number of Participants With Asthma Exacerbations During Study Period9697193
SecondaryNumber of Participants Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period

Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma

Time frame:
From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with health care encounters during this period is presented.
Reported as:
Count of participants · Participants
Number of Participants Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period
ParticipantsBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Number of Participants Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period252853
SecondaryChange of Blood Eosinophils Count

Change from Baseline to End of Treatment in blood eosinophils count.

Time frame:
From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Reported as:
Mean · cell/uL
Change of Blood Eosinophils Count
cell/uLBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Change of Blood Eosinophils Count12.3 ± 50.24-12.9 ± 212.51-0.5 ± 155.68
SecondaryNumber of Participants With Anti-drug Antibodies (ADA) Responses During the Study

Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study

Time frame:
From week 0 to week 184 in study treatment period and plus 12 weeks follow up period
Reported as:
Number · Participants
Number of Participants With Anti-drug Antibodies (ADA) Responses During the Study
ParticipantsBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Positive at any visit192847
Both baseline and post-baseline positive111728
Only post-baseline positive71017
ADA Persistently Positive122133
ADA Transiently Positive6612
Only baseline positive112
nAb positive132437
nAb positive in ADA positive participants132437
SecondaryDuration of Exposure

Duration of exposure

Time frame:
From week 0 to week 184 in study treatment period
Reported as:
Mean · months
Duration of Exposure
monthsBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Duration of Exposure26.35 ± 10.11225.36 ± 9.93925.85 ± 10.026

Adverse events

Collected over All participants completed treatment period up to Week 184.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benra 30 mg q.4 Weeks1/220 (0.5%)44/220 (20%)169/220 (76.8%)
Benra 30 mg q.8 Weeks0/226 (0%)47/226 (20.8%)145/226 (64.2%)
Most frequent serious events
Showing 10 of 89
Most frequent serious events
EventBenra 30 mg q.4 WeeksBenra 30 mg q.8 Weeks
AsthmaRespiratory, thoracic and mediastinal disorders9/22013/226
InfluenzaInfections and infestations3/2200/226
AstheniaGeneral disorders2/2200/226
Lower limb fractureInjury, poisoning and procedural complications2/2200/226
PneumoniaInfections and infestations1/2202/226
Limb injuryInjury, poisoning and procedural complications0/2202/226
Aortic valve stenosisCardiac disorders1/2200/226
Coronary artery occlusionCardiac disorders1/2200/226
Left ventricular failureCardiac disorders1/2200/226
CataractEye disorders1/2201/226
Most frequent other events
Showing 10 of 24
Most frequent other events
EventBenra 30 mg q.4 WeeksBenra 30 mg q.8 Weeks
NasopharyngitisInfections and infestations67/22064/226
HeadacheNervous system disorders32/22021/226
Viral upper respiratory tract infectionInfections and infestations29/22019/226
HypertensionVascular disorders14/22024/226
BronchitisInfections and infestations23/22022/226
AsthmaRespiratory, thoracic and mediastinal disorders16/22020/226
SinusitisInfections and infestations17/22010/226
Upper respiratory tract infectionInfections and infestations14/2208/226
Acute sinusitisInfections and infestations13/2208/226
Bronchitis bacterialInfections and infestations12/2209/226

Baseline characteristics

Full analysis set is defined to include subjects who received at least 1 dose of investigational product (IP).

Age, Continuous
Age, Continuous(Years)Benra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Mean53.5 ± 12.0053.0 ± 11.6453.2 ± 11.81
Sex: Female, Male
Sex: Female, Male(Participants)Benra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
Female140144284
Male8082162
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksTotal
White204206410
Black or African91322
American Asian538
Other246
08

Study locations

178 sites
  • Research Site
    Scottsboro, Alabama 35768, United States
  • Research Site
    Glendale, Arizona 85306, United States
  • Research Site
    Phoenix, Arizona 85012, United States
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Redondo Beach, California 90277, United States
  • Research Site
    Roseville, California 95661, United States
  • Research Site
    Sacramento, California 95825, United States
  • Research Site
    San Jose, California 95117, United States
  • Research Site
    Stockton, California 95204, United States
  • Research Site
    Westminster, California 92683, United States
  • Research Site
    Woodland, California 95695, United States
  • Research Site
    Colorado Springs, Colorado 80907, United States
  • Research Site
    Denver, Colorado 80206, United States
  • Research Site
    Wheat Ridge, Colorado 80033, United States
  • Research Site
    New Haven, Connecticut 06520, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    Doral, Florida 33172, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Miami, Florida 33134, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Miami, Florida 33176, United States
  • Research Site
    Orlando, Florida 32819, United States
  • Research Site
    Orlando, Florida 32825, United States
  • Research Site
    Winter Park, Florida 32789, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Bangor, Maine 04401, United States
  • Research Site
    Quincy, Massachusetts 02169, United States
  • Research Site
    Farmington Hills, Michigan 48334, United States
  • Research Site
    Flint, Michigan 48504, United States
  • Research Site
    Traverse City, Michigan 49686, United States
  • Research Site
    Bronx, New York 10461, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Cincinnati, Ohio 45231, United States
  • Research Site
    Middleburg Heights, Ohio 44130, United States
  • Research Site
    Oklahoma City, Oklahoma 73103, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    Jefferson Hills, Pennsylvania 15025, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Hodges, South Carolina 29653, United States
  • Research Site
    Rapid City, South Dakota 57702, United States
  • Research Site
    Dallas, Texas 75225, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    Houston, Texas 77058, United States
  • Research Site
    Houston, Texas 77081, United States
  • Research Site
    Houston, Texas 77083, United States
  • Research Site
    McKinney, Texas 75069, United States
  • Research Site
    Abingdon, Virginia 24210, United States
  • Research Site
    Falls Church, Virginia 22044, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Buenos Aires, C1414AIF, Argentina
  • Research Site
    Ciudad de Buenos Aire, C1121 ABE, Argentina
  • Research Site
    La Plata, B1902COS, Argentina
  • Research Site
    Mendoza, 5500, Argentina
  • Research Site
    Mendoza, M5500GIP, Argentina
  • Research Site
    Frankston, 3199, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    Parkville, 3050, Australia
  • Research Site
    Randwick, 2031, Australia
  • Research Site
    Woolloongabba, 4102, Australia
  • Research Site
    Pazardzhik, 4400, Bulgaria
  • Research Site
    Pernik, 2300, Bulgaria
  • Research Site
    Petrich, 2850, Bulgaria
  • Research Site
    Ruse, 7002, Bulgaria
  • Research Site
    Sliven, 8800, Bulgaria
  • Research Site
    Vratsa, 3000, Bulgaria
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Sherwood Park, Alberta T8L 0N2, Canada
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    Hamilton, Ontario L8N 4A6, Canada
  • Research Site
    Ottawa, Ontario K1G 6C6, Canada
  • Research Site
    Montreal, Quebec H2W 1T8, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Quebec, G1G 3Y8, Canada
  • Research Site
    Quebec, G1V 4G5, Canada
  • Research Site
    Quillota, 2260000, Chile
  • Research Site
    Talcahuano, 4270918, Chile
  • Research Site
    Valparaiso, 2341131, Chile
  • Research Site
    Karlovy Vary, 360 17, Czechia
  • Research Site
    Plzen, 304 60, Czechia
  • Research Site
    Praha, 130 00, Czechia
  • Research Site
    Rokycany, 337 22, Czechia
  • Research Site
    Brest Cedex 2, 29609, France
  • Research Site
    Dijon Cedex, 21079, France
  • Research Site
    Le Kremlin Bicêtre, 94275, France
  • Research Site
    Le Mans Cedex, 72037, France
  • Research Site
    Lyon Cedex 04, 69317, France
  • Research Site
    Marseille Cedex 20, 13915, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Paris, 75018, France
  • Research Site
    Pringy Cedex, 74374, France
  • Research Site
    Saint Pierre, 97448, France
  • Research Site
    Strasbourg Cedex, 67091, France
  • Research Site
    Toulouse Cedex 9, 31059, France
  • Research Site
    Aschaffenburg, 63739, Germany
  • Research Site
    Bamberg, 96049, Germany
  • Research Site
    Berlin, 10367, Germany
  • Research Site
    Frankfurt/Main, 60389, Germany

Showing the first 100 of 178 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Jun 2020, 47 months.

Results were first posted in Apr 2021, 9 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 47 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2016
First posted
Jun 22, 2016
StartActual
Jun 30, 2016
Primary completionActual
Jun 18, 2020
CompletionActual
Jun 18, 2020
Results first posted
Apr 13, 2021
Last update
Apr 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02808819
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 22, 2016
Start date
Jun 30, 2016
Primary completion
Jun 18, 2020
Completion
Jun 18, 2020
Results posted
Apr 13, 2021
Last update
Apr 13, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion